Patent classifications
C12Y401/02042
Genomic engineering of biosynthetic pathways leading to increased NADPH
The disclosure relates to host cells having altered NADPH availability, allowing for increased production of compounds produced using NADPH, and methods of use thereof. NADPH availability is altered by one or more of: expressing an altered GAPDH, expressing a variant glutamate dehydrogenase (gdh), aspartate semialdehyde dehydrogenase (asd), dihydropicolinate reductase (dapB), and meso-diaminopimelate dehydrogenase (ddh), expressing a novel nicotinamide nucleotide transhydrogenase, expressing a novel threonine aldolase, and expressing or modulating the expression of a pyruvate carboxylase in the host cells.
GENOMIC ENGINEERING OF BIOSYNTHETIC PATHWAYS LEADING TO INCREASED NADPH
The disclosure relates to host cells having altered NADPH availability, allowing for increased production of compounds produced using NADPH, and methods of use thereof. NADPH availability is altered by one or more of: expressing an altered GAPDH, expressing a variant glutamate dehydrogenase (gdh), aspartate semialdehyde dehydrogenase (asd), dihydropicolinate reductase (dapB), and meso-diaminopimelate dehydrogenase (ddh), expressing a novel nicotinamide nucleotide transhydrogenase, expressing a novel threonine aldolase, and expressing or modulating the expression of a pyruvate carboxylase in the host cells.
GENOMIC ENGINEERING OF BIOSYNTHETIC PATHWAYS LEADING TO INCREASED NADPH
The disclosure relates to host cells having altered NADPH availability, allowing for increased production of compounds produced using NADPH, and methods of use thereof. NADPH availability is altered by one or more of: expressing an altered GAPDH, expressing a variant glutamate dehydrogenase (gdh), aspartate semialdehyde dehydrogenase (asd), dihydropicolinate reductase (dapB), and meso-diaminopimelate dehydrogenase (ddh), expressing a novel nicotinamide nucleotide transhydrogenase, expressing a novel threonine aldolase, and expressing or modulating the expression of a pyruvate carboxylase in the host cells.
PRODUCTION OF GLYCINE BY FERMENTATION
The present invention concerns a metabolically engineered microorganism for glycine bioproduction or a salt or an ester thereof, the genome of said microorganism comprises an attenuation of the expression of genes encoding enzymes having glycine cleavage system activity as defined by E.C. 1.4.1.27 together with an overexpressing of threonine dehydrogenase dependent pathway as defined by EC E.C. 1.1.1.103 and E.C. 2.3.1.29 and/or with a threonine aldolase dependent pathway as defined by E.C. 4.1.2.48 or EC 4.1.2.42 or any of its catalytically active variants, its use for the production of glycine or one of its salts or esters. The present invention also concerns a fermentation process using said metabolically engineered microorganism for the production of glycine or one of its salts or esters.